Which Psychedelic Company Is Closest to FDA Approval?
A tracked, falsifiable answer from OOTWOracle · updated August 17, 2026
No psychedelic company has an FDA-approved product yet. As of August 17, 2026, MDMA-assisted therapy for PTSD (Lykos Therapeutics) advanced furthest into the process but received an FDA complete response letter requiring another Phase 3 trial, resetting its timeline. COMPASS Pathways' psilocybin program (COMP360) is the furthest-along active Phase 3 effort, in treatment-resistant depression. So the honest answer is: closest in the regulatory process is MDMA (but delayed); closest with active late-stage trials running is COMPASS. The Oracle currently puts it at 74% that under-skin ketamine study will report safety only, no approval impact (resolves 2026-11-30).
Several companies are racing toward the first FDA-approved psychedelic medicine, but 'closest' depends on how you count: furthest through the regulatory process, or furthest with trials actively running. Both answers matter, and neither has crossed the finish line. Here is the grounded picture, with the Oracle's dated odds attached.
Current odds on this question
| Oracle odds | Prediction (falsifiable) | Resolves |
|---|
| 74% | Under-skin ketamine study will report safety only, no approval impact | 2026-11-30 |
| 72% | VA psilocybin news won't give COMPASS a new FDA boost | 2026-11-13 |
| 70% | No psychedelic drug review panel meeting set before December 2026 | 2026-11-30 |
| 70% | Psilocybin for anxiety and alcohol problems won't reach FDA talks soon | 2026-11-04 |
| 68% | No official FDA meeting scheduled for TRP-8803 drug program anytime soon | 2026-10-28 |
Every row is a public, dated, falsifiable prediction — scored against a written resolution rule when the date arrives. Methodology & hit-rate: the track record.
Frequently asked
Has any psychedelic been FDA-approved?
No. As of August 17, 2026, no psilocybin or MDMA product has FDA marketing approval; both remain Schedule I federally.
Is Lykos (MDMA) or COMPASS (psilocybin) closer?
Lykos went furthest in the formal review but was sent back for another Phase 3, which delayed it. COMPASS has the furthest-along active Phase 3 program. 'Closest' depends on which you weight.
Could the first approval come in 2026?
The Oracle's odds favor no full FDA approval of a psychedelic in 2026; the nearest realistic path is a tightly-controlled approval later, after additional confirmatory data.
What about smaller players like atai or MindMed?
They have programs in earlier or mid-stage development. Being in trials is not the same as nearing approval — watch for Phase 3 readouts and accepted New Drug Applications, not press language.